Can a new injection smooth away frown lines?
NCT ID NCT07783763
First seen Aug 25, 2026 · Last updated Aug 27, 2026 · Updated 2 times
Summary
This trial tests whether DWP450, a form of botulinum toxin type A, can safely reduce moderate-to-severe frown lines (glabellar lines) in Japanese adults aged 18 to 64. Participants receive either DWP450 or a placebo injection, and researchers measure how many show improvement in frown lines at maximum frown and at rest. The study aims to see if this treatment offers a reliable cosmetic option for this population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Clostridium botulinum toxin type A (DWP450)
- What this could lead to
- If successful, this could offer a new, safe option for reducing frown lines in Japanese adults.
- What could go wrong
- This is a phase 3 trial, but results may not apply to all populations. Possible side effects include injection-site reactions or temporary muscle weakness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female participants aged 18 to 64 years at the time of informed consent who have been Japanese nationals since birth * At both the Screening Visit (Visit 1) and the Baseline Visit (Visit 2), a DW-FWS score of ≥2 (moderate) for glabellar lines at maximum frown, as assessed by the investigator at the study site * Subjects who are able to understand and comply with the study procedures and visit schedule * Subjects who have voluntarily provided written informed consent to participate in this clinical study Exclusion Criteria: * Subjects who are judged by the investigator to have glabellar lines that are not expected to improve sufficiently due to limitations, such as wrinkles at rest that do not disappear when manually stretched. * Subjects who plan to undergo treatment with botulinum toxin products or any facial cosmetic procedures that may affect glabellar or forehead wrinkles (e.g. filler injections, photorejuvenation therapy, chemical peels, anti-wrinkle treatments, facelift, etc.) during the period from the Screening Visit (V1) to the End-of-Study Visit including the extension period. * Female and male subjects of childbearing potential who are planning pregnancy during the study period or who are unwilling to use acceptable methods of contraception (pregnant or breastfeeding women are also excluded.) * Subjects who have participated in another clinical trial and received or used an investigational drug or medical device within 1 month (4 weeks) prior to the Screening Visit (V1). * Subjects who have a significant medical history that is considered by the investigator to make them unsuitable for participation in this clinical study (e.g., malignancy, immunodeficiency, cardiovascular disease, pulmonary disease, renal disease, hepatic disease, alcohol or drug dependence, psychiatric disorders, etc.).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glabellar lines are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two injection punch smooth frown lines better?
- New wrinkle treatment aims to rival botox in Head-to-Head trial
- New wrinkle treatment shows promise in asian trial
- New frown line combo treatment under study
- New Frown-Line treatment shows promise in large trial
- New combo treatment targets Crow's feet and hollow eyes